Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

WIB_icon

Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML

Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...

Is Chronic Lymphocytic Leukemia Curable With Newer Agents?

Chronic lymphocytic leukemia (CLL) has long been considered an incurable disease. The goal of traditional frontline treatments is to minimize disease burden and allow...

EURO-SKI: Can Patients With CML Stop Tyrosine Kinase Inhibitors?

Treatment with tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib, has increased the rates of survival and response over previously available therapies for...

Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment

Patients with previously untreated chronic myeloid leukemia (CML) who received bosutinib were more likely than those who received imatinib to respond to treatment and...
WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...

FDA Approves Nilotinib for Frontline and Secondline Use in Pediatric CML

The FDA approved nilotinib for first- and secondline use in pediatric patients (≥1 year) with Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CP-CML). Approval was...

What are the treatment options for a pregnant woman with chronic-phase CML?

This month Ayalew Tefferi, MD, discusses managing a pregnant patient with chronic-phase (CP) chronic myeloid leukemia (CML). And don't forget to check out next month's clinical...

Examining the Risk of Cardiovascular Disease–Related Mortality in Patients With and MDS/CMML

Patients with chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) have a higher risk of cardiovascular disease (CVD)–related mortality and cerebrovascular accident (CVA)–related mortality,...
WIB_icon

Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies

The oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib appeared to be active and tolerable at a range of doses and across a variety of...

FDA Expands Approval for Bosutinib to Include Early-Phase CML

The oral tyrosine kinase inhibitor bosutinib received expanded approval from the U.S. Food and Drug Administration (FDA) to treat adults with newly diagnosed Philadelphia...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.